Center Laboratories, Inc. (TPEX:4123)

Market Cap	24.64B
Revenue (ttm)	1.62B
Net Income (ttm)	-1.10B
Shares Out	720.42M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	0.75 (2.21%)
Ex-Dividend Date	Aug 2, 2024

Volume	476,346
Average Volume	1,340,899
Open	34.30
Previous Close	34.30
Day's Range	33.90 - 34.40
52-Week Range	30.60 - 59.60
Beta	0.64
RSI	39.16
Earnings Date	May 12, 2025

About Center Laboratories

Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising of antipyretic and analgesic, bronchodilator, anti-inflammatory preparations, anti-allergic agent, expectorant, narcotic antitussive and expectorant, gastrointestinal preparations, non-narcotic antitussive and expectorant, and other medicines. It also offers central nervous system medication consisting of cerebrovascular disease, dementia, depressi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4123

Financial Performance

In 2024, Center Laboratories's revenue was 1.62 billion, an increase of 16.06% compared to the previous year's 1.39 billion. Losses were -1.10 billion, 10.9% more than in 2023.